Alumis

Alumis FCF/Debt

The Free Cash Flow to Debt Ratio of Alumis (ALMS) as of Oct 17, 2026 is -7,926.68 %.

FCF/Debt

-7,926.68 %

Last updated:

Free Cash Flow to Debt Ratio of Alumis is 2025 -7,926.68 % . Free Cash Flow to Debt Ratio of Alumis was 2024 - . It decreases by % lower compared to the previous year.

The Alumis FCF/Debt history

The Alumis FCF/Debt history
YEARFCF/DebtYoY
-7,926.68 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alumis Stock analysis

What does Alumis do? Alumis Inc, headquartered in South San Francisco, California, is a clinical-stage biopharmaceutical company operating in the Pharmaceuticals sector. The company develops TYK2 inhibitors ESK-001 for plaque psoriasis, lupus, and uveitis, and A-005 for neuroinflammatory and neurodegenerative diseases. With 221 employees, Alumis focuses on immune-mediated diseases through monotherapy and combination therapies, leveraging data analytics to identify potential treatment targets. Alumis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alumis stock

Free Cash Flow to Debt Ratio of Alumis is -7,926.68 % in 2025.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Alumis since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Alumis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Alumis

All Key Metrics — Alumis